Christian Delloye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Christian Delloye has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Olivier Cornu
Division of Orthopedics and Musculoskeletal Trauma, Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium
6 shared publications A Vincent
5 shared publicationsP De Nayer
3 shared publicationsA. Vincent
2 shared publicationsJ E Dubuc
2 shared publicationsL Coutelier
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 1 May 2007
- Published by British Editorial Society of Bone & Joint Surgery in The Journal of Bone and Joint Surgery. British volume
- Vol. 89-B (5) , 574-580
Bone allografts
Bone allografts can be used in any kind of surgery involving bone from minor defects to major bone loss after tumour resection. This review describes the various types of bone grafts and the current knowledge on bone allografts, from procurement and preparation to implantation. The surgical conditions for optimising the incorporation of bone are outlined, and surgeon expectations from a bone allograft discussed.
- 1 May 2007
- Published by British Editorial Society of Bone & Joint Surgery in The Journal of Bone and Joint Surgery. British volume
- Vol. 89-B (5) , 574-580
Top Cited PapersOpen AccessBone allografts
Bone allografts can be used in any kind of surgery involving bone from minor defects to major bone loss after tumour resection. This review describes the various types of bone grafts and the current knowledge on bone allografts, from procurement and preparation to implantation. The surgical conditions for optimising the incorporation of bone are outlined, and surgeon expectations from a bone allograft discussed.
- 1 March 2007
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 89 (3) , 579-587
Pelvic Reconstruction with a Structural Pelvic Allograft After Resection of a Malignant Bone Tumor
Background: Reconstruction of the pelvic arch after resection of a malignant pelvic tumor remains a major surgical challenge because of the high rate of associated complications. The purpose of this investigation was to assess the functional outcome and complication rate following treatment with a bone allograft to reconstruct the pelvis. Methods: Twenty-four consecutive patients underwent excision of a malignant pelvic bone tumor and reconstruction with a pelvic bone allograft. The living patients were followed for a minimum of twenty-four months. There were nineteen primary malignant bone tumors, sixteen of which were high-grade sarcomas, and there were five isolated metastases. Patients were examined clinically and radiographically and were assessed functionally with the Musculoskeletal Tumor Society score. Results: The mean age of the patients at the time of the index surgery was thirty-four years, and the mean duration of follow-up was forty-one months. Eighteen of the twenty-four resections involved the periacetabular area and were followed by reconstruction either with a hip prosthesis (thirteen) or with an osteochondral allograft alone (five). The six other resections involved the iliac bone. All patients received a massive bone allograft that had been sterilely procured without secondary irradiation. At the time of our last evaluation, eight patients were alive and free of disease. Seven patients had a local recurrence. Neurological deficits were present in six patients, and three had a deep infection. Nonunion of three of the sixteen allografts that could be evaluated was observed. Neither graft fracture nor lysis was observed. Eleven patients underwent surgical revision, with nine of these revisions related to the reconstruction. The average Musculoskeletal Tumor Society score at the time of the latest follow-up was 73% of the maximal possible score. The average score was 82% for the eleven patients with an age of less than twenty years at the time of the index procedure and 65% for the thirteen older patients. Ten patients walked without any assistive device, and five of them had normal function with no or only a slight limp. Conclusions: Pelvic reconstruction after a limb-sparing resection is associated with a high risk of surgical complications and usually should be reserved for patients with a primary bone sarcoma. A pelvic allograft can restore the anatomy and provide good functional results, especially in young patients. Nonunion was the most common allograft-related complication. Level of Evidence: Therapeutic Level IV. See Instructions to Authors for a complete description of levels of evidence.
- 1 March 2007
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 89 (3) , 579-587
Pelvic Reconstruction with a Structural Pelvic Allograft After Resection of a Malignant Bone Tumor
Background: Reconstruction of the pelvic arch after resection of a malignant pelvic tumor remains a major surgical challenge because of the high rate of associated complications. The purpose of this investigation was to assess the functional outcome and complication rate following treatment with a bone allograft to reconstruct the pelvis. Methods: Twenty-four consecutive patients underwent excision of a malignant pelvic bone tumor and reconstruction with a pelvic bone allograft. The living patients were followed for a minimum of twenty-four months. There were nineteen primary malignant bone tumors, sixteen of which were high-grade sarcomas, and there were five isolated metastases. Patients were examined clinically and radiographically and were assessed functionally with the Musculoskeletal Tumor Society score. Results: The mean age of the patients at the time of the index surgery was thirty-four years, and the mean duration of follow-up was forty-one months. Eighteen of the twenty-four resections involved the periacetabular area and were followed by reconstruction either with a hip prosthesis (thirteen) or with an osteochondral allograft alone (five). The six other resections involved the iliac bone. All patients received a massive bone allograft that had been sterilely procured without secondary irradiation. At the time of our last evaluation, eight patients were alive and free of disease. Seven patients had a local recurrence. Neurological deficits were present in six patients, and three had a deep infection. Nonunion of three of the sixteen allografts that could be evaluated was observed. Neither graft fracture nor lysis was observed. Eleven patients underwent surgical revision, with nine of these revisions related to the reconstruction. The average Musculoskeletal Tumor Society score at the time of the latest follow-up was 73% of the maximal possible score. The average score was 82% for the eleven patients with an age of less than twenty years at the time of the index procedure and 65% for the thirteen older patients. Ten patients walked without any assistive device, and five of them had normal function with no or only a slight limp. Conclusions: Pelvic reconstruction after a limb-sparing resection is associated with a high risk of surgical complications and usually should be reserved for patients with a primary bone sarcoma. A pelvic allograft can restore the anatomy and provide good functional results, especially in young patients. Nonunion was the most common allograft-related complication. Level of Evidence: Therapeutic Level IV. See Instructions to Authors for a complete description of levels of evidence.
- 1 October 2005
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 87 (10) , 2253-2258
TREATMENT OF ANEURYSMAL BONE CYSTS BY INTRODUCTION OF DEMINERALIZED BONE AND AUTOGENOUS BONE MARROW
Background: On the assumption that an aneurysmal bone cyst has an intrinsic potential to heal by ossification, a new, minimally invasive protocol was developed. Demineralized bone powder mixed with bone-marrow aspirate was introduced into the cyst to halt the expansion phase and to allow the cyst to ossify. We hypothesized that, in order to induce bone-healing, cells from the cyst are needed to respond to the inductive material but that curettage or extensive surgery is not necessary. The goals of the present study were to assess cyst-healing and to determine the prevalence of recurrence associated with this new procedure. Methods: Thirteen biopsy-proven primary aneurysmal bone cysts were entered through a small incision, and a paste of demineralized bone and autologous bone marrow was introduced with an applicator. The study group included three male and ten female patients with a mean age of 16.6 years. The cyst was located in a long bone in six patients, the pelvis in five patients, and the scapular glenoid and the calcaneus in one patient each. Five patients had not received treatment previously, whereas one had had a preoperative embolization and seven had recurrent lesions that had been treated previously. Results: After a mean duration of follow-up of 3.9 years, healing was achieved in eleven patients. Conclusions: This minimally invasive method is able to promote the self-healing of a primary aneurysmal bone cyst. As no curettage is required, the proposed treatment avoids extensive surgery and blood loss and is convenient for the treatment of poorly accessible lesions such as those occurring in the pelvis. Level of Evidence: Therapeutic Level IV. See Instructions to Authors for a complete description of levels of evidence.
- 1 October 2005
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 87 (10) , 2253-2258
TREATMENT OF ANEURYSMAL BONE CYSTS BY INTRODUCTION OF DEMINERALIZED BONE AND AUTOGENOUS BONE MARROW
Background: On the assumption that an aneurysmal bone cyst has an intrinsic potential to heal by ossification, a new, minimally invasive protocol was developed. Demineralized bone powder mixed with bone-marrow aspirate was introduced into the cyst to halt the expansion phase and to allow the cyst to ossify. We hypothesized that, in order to induce bone-healing, cells from the cyst are needed to respond to the inductive material but that curettage or extensive surgery is not necessary. The goals of the present study were to assess cyst-healing and to determine the prevalence of recurrence associated with this new procedure. Methods: Thirteen biopsy-proven primary aneurysmal bone cysts were entered through a small incision, and a paste of demineralized bone and autologous bone marrow was introduced with an applicator. The study group included three male and ten female patients with a mean age of 16.6 years. The cyst was located in a long bone in six patients, the pelvis in five patients, and the scapular glenoid and the calcaneus in one patient each. Five patients had not received treatment previously, whereas one had had a preoperative embolization and seven had recurrent lesions that had been treated previously. Results: After a mean duration of follow-up of 3.9 years, healing was achieved in eleven patients. Conclusions: This minimally invasive method is able to promote the self-healing of a primary aneurysmal bone cyst. As no curettage is required, the proposed treatment avoids extensive surgery and blood loss and is convenient for the treatment of poorly accessible lesions such as those occurring in the pelvis. Level of Evidence: Therapeutic Level IV. See Instructions to Authors for a complete description of levels of evidence.
- 1 October 2005
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 87 (10) , 2253-2258
Treatment of Aneurysmal Bone Cysts by Introduction of Demineralized Bone and Autogenous Bone Marrow
Background: On the assumption that an aneurysmal bone cyst has an intrinsic potential to heal by ossification, a new, minimally invasive protocol was developed. Demineralized bone powder mixed with bone-marrow aspirate was introduced into the cyst to halt the expansion phase and to allow the cyst to ossify. We hypothesized that, in order to induce bone-healing, cells from the cyst are needed to respond to the inductive material but that curettage or extensive surgery is not necessary. The goals of the present study were to assess cyst-healing and to determine the prevalence of recurrence associated with this new procedure. Methods: Thirteen biopsy-proven primary aneurysmal bone cysts were entered through a small incision, and a paste of demineralized bone and autologous bone marrow was introduced with an applicator. The study group included three male and ten female patients with a mean age of 16.6 years. The cyst was located in a long bone in six patients, the pelvis in five patients, and the scapular glenoid and the calcaneus in one patient each. Five patients had not received treatment previously, whereas one had had a preoperative embolization and seven had recurrent lesions that had been treated previously. Results: After a mean duration of follow-up of 3.9 years, healing was achieved in eleven patients. Conclusions: This minimally invasive method is able to promote the self-healing of a primary aneurysmal bone cyst. As no curettage is required, the proposed treatment avoids extensive surgery and blood loss and is convenient for the treatment of poorly accessible lesions such as those occurring in the pelvis. Level of Evidence: Therapeutic Level IV. See Instructions to Authors for a complete description of levels of evidence.
- 1 October 2005
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 87 (10) , 2253-2258
Treatment of Aneurysmal Bone Cysts by Introduction of Demineralized Bone and Autogenous Bone Marrow
Background: On the assumption that an aneurysmal bone cyst has an intrinsic potential to heal by ossification, a new, minimally invasive protocol was developed. Demineralized bone powder mixed with bone-marrow aspirate was introduced into the cyst to halt the expansion phase and to allow the cyst to ossify. We hypothesized that, in order to induce bone-healing, cells from the cyst are needed to respond to the inductive material but that curettage or extensive surgery is not necessary. The goals of the present study were to assess cyst-healing and to determine the prevalence of recurrence associated with this new procedure. Methods: Thirteen biopsy-proven primary aneurysmal bone cysts were entered through a small incision, and a paste of demineralized bone and autologous bone marrow was introduced with an applicator. The study group included three male and ten female patients with a mean age of 16.6 years. The cyst was located in a long bone in six patients, the pelvis in five patients, and the scapular glenoid and the calcaneus in one patient each. Five patients had not received treatment previously, whereas one had had a preoperative embolization and seven had recurrent lesions that had been treated previously. Results: After a mean duration of follow-up of 3.9 years, healing was achieved in eleven patients. Conclusions: This minimally invasive method is able to promote the self-healing of a primary aneurysmal bone cyst. As no curettage is required, the proposed treatment avoids extensive surgery and blood loss and is convenient for the treatment of poorly accessible lesions such as those occurring in the pelvis. Level of Evidence: Therapeutic Level IV. See Instructions to Authors for a complete description of levels of evidence.
- 1 December 2004
- Vol. 70 (6) , 591-7
Treatment of allograft nonunions with recombinant human bone morphogenetic proteins (rhBMP).
Fractures and nonunions are the main complications associated with bone allografts. Although the osteogenic role of recombinant human bone morphogenetic proteins (rhBMPs) has been demonstrated in experimental models and human tibial nonunions, the results are unknown for allograft nonunions. In this study, the efficacy of rhBMPs was evaluated in nonunions of femoral allografts. The results of six allograft nonunions in five patients who underwent resection of malignant bone tumours and allograft bone transplantation were analysed one to five years following application of rhBMPs at the nonunion site. There were two osteoarticular allografts and three intercalary allografts. Of three intercalary allografts, one demonstrated nonunion at both ends. Four patients received adjuvant chemotherapy and three had additional radiation therapy. There were two allograft fracture nonunions and four nonunions at the allograft-host junction. Two allograft fracture nonunions and one nonunion at the allograft-host junction were treated with 12 mg of rhBMP-2. The remaining three nonunions were treated with 7 mg of rhBMP-7 (Osigraft). The outcome and radiological evidence of healing were evaluated at a minimal follow-up of twelve months. There was neither healing of allograft fractures nor union of allograft-host junction. There was elongation or enlargement of the callus from the host. One patient continued to develop resorption of the allograft, which led to allograft fracture. Two patients who were treated with rhBMP-7 and corticocancellous allografts developed sterile drainage. There was no tumour recurrence with the use of rhBMPs after a mean follow-up of 39+/-25 months. rhBMP's alone were not sufficient to achieve healing in allograft nonunions and fractures following wide resection including periosteum and soft tissues.
- 1 December 2004
- Vol. 70 (6) , 591-7
Treatment of allograft nonunions with recombinant human bone morphogenetic proteins (rhBMP).
Fractures and nonunions are the main complications associated with bone allografts. Although the osteogenic role of recombinant human bone morphogenetic proteins (rhBMPs) has been demonstrated in experimental models and human tibial nonunions, the results are unknown for allograft nonunions. In this study, the efficacy of rhBMPs was evaluated in nonunions of femoral allografts. The results of six allograft nonunions in five patients who underwent resection of malignant bone tumours and allograft bone transplantation were analysed one to five years following application of rhBMPs at the nonunion site. There were two osteoarticular allografts and three intercalary allografts. Of three intercalary allografts, one demonstrated nonunion at both ends. Four patients received adjuvant chemotherapy and three had additional radiation therapy. There were two allograft fracture nonunions and four nonunions at the allograft-host junction. Two allograft fracture nonunions and one nonunion at the allograft-host junction were treated with 12 mg of rhBMP-2. The remaining three nonunions were treated with 7 mg of rhBMP-7 (Osigraft). The outcome and radiological evidence of healing were evaluated at a minimal follow-up of twelve months. There was neither healing of allograft fractures nor union of allograft-host junction. There was elongation or enlargement of the callus from the host. One patient continued to develop resorption of the allograft, which led to allograft fracture. Two patients who were treated with rhBMP-7 and corticocancellous allografts developed sterile drainage. There was no tumour recurrence with the use of rhBMPs after a mean follow-up of 39+/-25 months. rhBMP's alone were not sufficient to achieve healing in allograft nonunions and fractures following wide resection including periosteum and soft tissues.
- 1 June 2004
- Published by Elsevier in Revue de Chirurgie Orthopedique Et Reparatrice de L'appareil Moteur
- Vol. 90 (4) , 360-364
Reconstruction du coude par allogreffe massive ostéo-articulaire totale : échec précoce par instabilité
- 1 June 2004
- Published by Elsevier in Revue de Chirurgie Orthopedique Et Reparatrice de L'appareil Moteur
- Vol. 90 (4) , 360-364
Reconstruction du coude par allogreffe massive ostéo-articulaire totale : échec précoce par instabilité
- 1 April 2003
- Vol. 69 (2) , 104-11
Incorporation of massive bone allografts: can we achieve better performance?
- 1 April 2003
- Vol. 69 (2) , 104-11
Incorporation of massive bone allografts: can we achieve better performance?
- 1 January 2003
- Vol. 69 (1) , 1-8
Bone substitutes in 2003: an overview.
The authors review the various bone substitutes which are currently available on the market place in Belgium. After describing the requirements for clinical use of such materials, they compare the biological and mechanical values of bone autografts, bone allografts, demineralised bone, xenografts, coral and synthetic materials such as calcium sulfate, calcium phosphate, ionic cement and bioactive glass. They stress the current paucity of data pertaining to the biological value of these materials and call for in vivo validation tests. They also review biomolecules such as BMP-2 or OP-1, whose osteoinductive properties are currently under investigation. Finally, they present the emergent field of cell therapy, in which osteoprogenitor cells are isolated from the patient's bone marrow and reinjected after in vitro cultivation. They stress the therapeutic and medicolegal problems raised by the combination of medical devices, grafts, medicinal products and cells, all of which have a different status within the complex European legal framework.
- 1 January 2003
- Vol. 69 (1) , 1-8
Bone substitutes in 2003: an overview.
The authors review the various bone substitutes which are currently available on the market place in Belgium. After describing the requirements for clinical use of such materials, they compare the biological and mechanical values of bone autografts, bone allografts, demineralised bone, xenografts, coral and synthetic materials such as calcium sulfate, calcium phosphate, ionic cement and bioactive glass. They stress the current paucity of data pertaining to the biological value of these materials and call for in vivo validation tests. They also review biomolecules such as BMP-2 or OP-1, whose osteoinductive properties are currently under investigation. Finally, they present the emergent field of cell therapy, in which osteoprogenitor cells are isolated from the patient's bone marrow and reinjected after in vitro cultivation. They stress the therapeutic and medicolegal problems raised by the combination of medical devices, grafts, medicinal products and cells, all of which have a different status within the complex European legal framework.
- 1 June 2002
- Vol. 88 (4) , 410-4
[Mechanical complications of total shoulder inverted prosthesis].
Our series of inverted prosthesis included 5 patients with a mean age of 73 +/- 6 years. In 4 cases, the implant was performed as a surgical revision. The follow up was 81 +/- 15 months. Three shoulders were pain free whereas two caused a dull pain after a free interval due to mechanical complications. The mean active elevation was 72 degrees while external rotation was - 2 degrees. The adjusted Constant score passed from 32 to 60. In case of complications, the score dropped to 32. Mechanical complications were important with in one case, an unscrening of the glenosphere and in two cases, a loosening of the glenoid prosthesis. This last and major complication occurred 6 years after surgery and was promoted by the occurrence of a progressive bone erosion in the scapula. This gap represented an attempt to accomodate the medial part of the humeral prosthesis under the scapula when the arm is at rest or in adduction. The concept of an inverted prosthesis is attractive and this implant remains one of the options in cuff-tear arthropathy. Our results were not as good as those reported by others but most of ours patients had been already operated before. The occurrence of an osseous gap on pilar of scapula may lead to failure of this prosthesis. This gap remains a threath as it can progress and as such warrants a design alteration of the prosthesis.
- 1 June 2002
- Vol. 88 (4) , 410-4
[Mechanical complications of total shoulder inverted prosthesis].
Our series of inverted prosthesis included 5 patients with a mean age of 73 +/- 6 years. In 4 cases, the implant was performed as a surgical revision. The follow up was 81 +/- 15 months. Three shoulders were pain free whereas two caused a dull pain after a free interval due to mechanical complications. The mean active elevation was 72 degrees while external rotation was - 2 degrees. The adjusted Constant score passed from 32 to 60. In case of complications, the score dropped to 32. Mechanical complications were important with in one case, an unscrening of the glenosphere and in two cases, a loosening of the glenoid prosthesis. This last and major complication occurred 6 years after surgery and was promoted by the occurrence of a progressive bone erosion in the scapula. This gap represented an attempt to accomodate the medial part of the humeral prosthesis under the scapula when the arm is at rest or in adduction. The concept of an inverted prosthesis is attractive and this implant remains one of the options in cuff-tear arthropathy. Our results were not as good as those reported by others but most of ours patients had been already operated before. The occurrence of an osseous gap on pilar of scapula may lead to failure of this prosthesis. This gap remains a threath as it can progress and as such warrants a design alteration of the prosthesis.